Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?

Sotagliflozin is a dual sodium-glucose co-transporter (SGLT) 2 inhibitor, manifesting a 20-fold higher inhibitory activity for SGLT2 than for SGLT1. Differences in SGLT2 over SGLT1 selectivity of the available agents have been proposed to relate to variability in efficacy and safety characteristics....

Descripción completa

Detalles Bibliográficos
Autores principales: Koufakis, Theocharis, Mustafa, Omar G., Tsimihodimos, Vasilios, Ajjan, Ramzi A., Kotsa, Kalliopi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Current Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261816/
https://www.ncbi.nlm.nih.gov/pubmed/34232488
http://dx.doi.org/10.1007/s40265-021-01559-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261816/
https://www.ncbi.nlm.nih.gov/pubmed/34232488
http://dx.doi.org/10.1007/s40265-021-01559-1

Ejemplares similares